do you mean IIL innate immunotherapeutics.
they are a totally different company who had their hopes and most of their market value pinned on the fate of a single phase 2 trial of a multiple sclerosis drug.
the trial failed and the sp plummeted.
so no they are not comparable. the risk here is legislative not a single trial. either way, most of the fear is already factored into the sp at $1 and the trump administration is backing away from any major legislation that would be massively damaging to myx.
there is of course downside risk here, but i think there is a lot more upside potential given the fact that there is a long pipeline of drugs to be released and the m&a plus capex should come to fruition over the next 2 fy's.
each to your own but i thinknif it drifts back to $1 it would be a good buy. i think at anything below 1.30 its still a strong buy.
MYX Price at posting:
$1.09 Sentiment: Buy Disclosure: Held
